HUSSAM KUJOK: Open Payments
NPI 1013081611 · CARMICHAEL, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$595 in 25 payments from 12 companies in 2025. Trend: 2023 $876 · 2024 $539 · 2025 $595
Food & beverage: $575Long term medical supply or device loan: $20
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $103 |
| PFIZER INC. | 3 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $79 |
| Novo Nordisk Inc | 3 | $73 |
| Lilly USA, LLC | 2 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $45 |
| Abbott Laboratories | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Exact Sciences Corporation | 1 | $24 |
Products named: TRELEGY ELLIPTA, PREVNAR 20, GEMTESA, MOUNJARO, Ozempic, VOQUEZNA, REXULTI, INSPIRE.
Industry payments across CA — which companies pay providers there.
